Douglas Gresham, MD
Endocrinology, Diabetes & Metabolism · Savannah, GANPI 1629155676
Payments from drug & device makers
Across 147 payments — averaging $20.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$505
- Mannkind Corporation$449
- Otsuka America Pharmaceutical, Inc.$429
- Insulet Corporation$225
- Medtronic$170
- OPKO Pharmaceuticals, LLC$167
- plus $1K from 21 others
What the payments were for
- Food & beverage$2,68190%
- Education$1726%
- Gifts$1194%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 36 | $505 |
| Mannkind Corporation | 14 | $449 |
| Otsuka America Pharmaceutical, Inc. | 19 | $429 |
| Insulet Corporation | 12 | $225 |
| Medtronic | 4 | $170 |
| OPKO Pharmaceuticals, LLC | 8 | $167 |
| Calliditas Therapeutics US Inc. | 7 | $141 |
| Vifor Pharma, Inc. | 6 | $135 |
| AstraZeneca | 7 | $120 |
| Travere Therapeutics, Inc. | 6 | $109 |
| Mallinckrodt Hospital Products Inc. | 5 | $103 |
| Averitas Pharma Inc. | 3 | $69 |
| Merck | 3 | $47 |
| Phathom Pharmaceuticals, Inc. | 2 | $33 |
| ANI Pharmaceuticals, Inc. | 2 | $33 |
| Lilly USA, LLC | 2 | $31 |
| Cequr Corporation | 1 | $25 |
| Dexcom, Inc. | 1 | $25 |
| Amgen | 1 | $21 |
| Bayer | 1 | $21 |
| Aurinia Pharma U.S., Inc. | 1 | $18 |
| Ascensia Diabetes Care US Inc. | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| Tosoh Bioscience, Inc. | 1 | $17 |
| Boehringer Ingelheim | 1 | $17 |
| Sumitomo Pharma America, Inc. | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$122
How this compares
$2,973 in reported general payments places this provider in the 45th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
See all endocrinology, diabetes & metabolism providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 499 | $820,184 |
| MounjaroTirzepatide | 253 | $360,724 |
| Tresiba Flextouch U-100Insulin Degludec | 241 | $210,587 |
| TrulicityDulaglutide | 116 | $169,030 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 105 | $150,388 |
| JardianceEmpagliflozin | 115 | $142,214 |
| FarxigaDapagliflozin Propanediol | 118 | $139,611 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 41 | $80,314 |
| JanuviaSitagliptin Phosphate | 63 | $79,013 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 394 | $67,307 |
| Tresiba Flextouch U-200Insulin Degludec | 34 | $67,108 |
| RybelsusSemaglutide | 37 | $61,804 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 66 | $58,141 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 34 | $54,303 |
| Humalog Kwikpen U-100Insulin Lispro | 190 | $49,868 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog, Fiasp | $505 | $922,615635 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $31 | $548,697438 claims |
| Boehringer IngelheimJardiance | $17 | $142,214115 claims |
| AstraZenecaFarxiga | $120 | $139,611118 claims |
| MerckJanuvia | $47 | $79,01363 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $11 | $33,64252 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
Other endocrinology, diabetes & metabolism in Savannah
- Ismary DecastroSavannah$169K
- Kaveh EhsanipoorSavannah$76K
- Joseph DehavenSavannah$58K
- Carolyn NelsonSavannah$25K
- James StoeverSavannah$11K
- Bruce BodeAtlanta$18.3M
- Gulliermo UmpierrezAtlanta$6.6M
- John ReedRoswell$5.7M
- Thomas JonesMacon$4.8M
- Steven LeichterColumbus$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.